Longitudinal analysis of urinary proteins in lupus nephritis – A pilot study

Carlsson, Emil; Quist, Alexandra; Davies, Joseph E.; Midgley, Angela; Smith, Eve; Bruce, Ian N; Beresford, Michael W.; Hedrich, Christian M.

doi:10.1016/j.clim.2022.108948

Cited by 5 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the aforementioned biomarkers, urinary MCP-1, NGAL, and CD163 deserve mention for their potential usefulness as indicators of response to therapy, as they have exhibited good predictive performances in multiple studies [ 35 , 72 , 79 , 87 , 101 , 136 ] (see Table 5 for the detailed metrics).…”

Section: Resultsmentioning

confidence: 99%

Current Insights on Biomarkers in Lupus Nephritis: A Systematic Review of the Literature

Palazzo

Lindblom

Mohan

et al. 2022

JCM

View full text Add to dashboard Cite

Lupus nephritis (LN) is a major cause of morbidity and mortality among patients with systemic lupus erythematosus (SLE). However, promising emerging biomarkers pave the way toward an improved management of patients with LN. We have reviewed the literature over the past decade, and we herein summarise the most relevant biomarkers for diagnosis, monitoring, and prognosis in LN. An initial systematic search of Medline was conducted to identify pertinent articles. A total of 104 studies were selected to be included in this review. Several diagnostic biomarkers, including MCP-1, TWEAK, NGAL, and uric acid, exhibited good ability to differentiate LN patients from non-renal SLE patients. Several cytokines and chemokines, including IL-10, IL-17, MCP-1, and IP-10, hold promise for assessing LN disease activity, as do cell adhesion molecules (CAMs). Angiogenesis-related and haemostasis-related proteins have also displayed potential for monitoring disease activity. Biomarkers of responses to therapy include Axl, CD163, and BAFF, whereas VCAM-1, ALCAM, and ANCAs have been reported as prognostic markers, along with traditional markers. In addition, novel renal tissue biomarkers may prove to be a useful complement to histological evaluations. The overall heterogeneity of the inclusion criteria and outcome measures across different studies, along with a lack of validation in multi-centre cohorts, call for future collaborative efforts. Nevertheless, we foresee that several biomarkers hold promise toward optimisation of the management of LN, with the use of integrated omics and panels of less invasive biomarkers paving the way towards personalised medicine.

show abstract

Section: Resultsmentioning

confidence: 99%

Current Insights on Biomarkers in Lupus Nephritis: A Systematic Review of the Literature

Palazzo

Lindblom

Mohan

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…In addition, multiple biomarkers combination measurements tend to outperform a single biomarker to better indicate efficacy. A research team used the urine proteome model composed of LPGDS, transferrin, AGP-1, ceruloplasmin, MCP-1 and sVCAM-1 as a potential biomarker group to identify active LN and predict the efficacy of RTX [51,52]. Other research teams have used adiponectin, MCP-1, sVCAM-1 and PF4 as optimal biomarker group models for diagnosing patients with proliferative LN [81].…”

Section: Discussionmentioning

confidence: 99%

“…There are many factors that affect the results of experiments, so there is no urine protein or proteome that has been applied to the clinical practice of LN. A research team believed that a urine proteome model consisting of lipocalinlike prostaglandin D synthase (LPGDS), transferrin, alpha-1-acid glycoprotein (AGP-1), ceruloplasmin, MCP-1 and soluble vascular cell adhesion molecule-1 (sVCAM-1) may be used as biomarkers for active LN and predict the efficacy of RTX [51,52].…”

Section: Targeted Inhibitors Of Cd20mentioning

confidence: 99%

Biomarkers Associated with Drugs for the Treatment of Lupus Nephritis

Nie,

Chang,

et al. 2023

Biomolecules

View full text Add to dashboard Cite

The constant updating of lupus drug treatment guidelines has led to a question. How can the efficacy of treatment be more effectively monitored? Systemic lupus erythematosus (SLE) is a complex autoimmune disease that often presents clinically with multi-organ involvement, and approximately 30% of patients with SLE develop lupus nephritis (LN). Therefore, it is important to better track disease progression and drug efficacy. Now, kidney biopsy is still the gold standard for diagnosing and guiding the treatment of LN, but it is invasive and expensive. If simple, non-invasive and effective biomarkers can be found, drug intervention and prognosis can be better monitored and targeted. In this review, we focus on LN and explore biomarkers related to LN therapeutics, providing clinicians with more possibilities to track the therapeutic effect of drugs, improve treatment options and assess patient outcomes.

show abstract

“…Current routine laboratory tests are inadequate for identifying and monitoring jSLE, therefore, assessment of novel biomarker candidates has become an active area of investigation [99]. The most promising candidates present in urine and blood, with panels of proteins increasing sensitivity and specificity for diagnosis, monitoring and predicting treatment response [100,101 ▪ ,102–104]. A comprehensive summary of promising biomarker candidates is included in Table 2.…”

Section: Monitoring Of Juvenile-onset Systemic Lupus Erythematosusmentioning

confidence: 99%

Current views on lupus in children

Smith

Lythgoe²,

Hedrich

2022

Current Opinion in Rheumatology

Self Cite

View full text Add to dashboard Cite

Purpose of reviewThis manuscript provides an update on clinical and pathophysiological features of juvenile-onset systemic lupus erythematosis (jSLE), challenges applying adult-derived classification criteria, and recent advances in treatment and care.Recent findingsSignificant scientific advances have improved the understanding of genetic factors (both genetic causes and risk alleles) and associated phenotypic features. Panels of urine/blood biomarker candidates aid in diagnosing jSLE, monitoring disease activity and predicting treatment response. Available classification criteria have been extensively assessed, with differences in clinical and immunological phenotypes of patients across age groups and ethnicities affecting their performance in jSLE. Therapeutic options remain limited and are based on protocols for adult-onset SLE patients. International efforts to inform development of a treat-to-target (T2T) approach for jSLE have yielded cohort-level evidence that target attainment reduces the risk of severe flare and new damage, and treatment compliance.SummaryRecent studies have significantly improved our understanding of jSLE pathogenesis, highlighting important differences between jSLE and adult SLE, and providing the basis of biomarker development and target-directed individualized treatment and care. Future work focused on development of a T2T approach in jSLE is eagerly awaited.

show abstract

Longitudinal analysis of urinary proteins in lupus nephritis – A pilot study

Cited by 5 publications

References 25 publications

Current Insights on Biomarkers in Lupus Nephritis: A Systematic Review of the Literature

Current Insights on Biomarkers in Lupus Nephritis: A Systematic Review of the Literature

Biomarkers Associated with Drugs for the Treatment of Lupus Nephritis

Current views on lupus in children

Contact Info

Product

Resources

About